The scientific backdrop is striking. Years before pivotal trial data existed, researchers including Ronald Grunstein and colleagues argued in the journal Sleep that incretin-based pharmacotherapy could positively disrupt the management of obesity-related sleep apnea, challenging the field’s heavy reliance on mechanical therapies and its limited engagement with weight management as a principal therapeutic strategy. That prediction has now matured into clinical reality. Tirzepatide, a dual agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, produces substantial weight reduction, and the SURMOUNT-OSA program demonstrated meaningful reductions in sleep-disordered breathing measures among participants with obesity. Secondary analyses published in Nature Medicine have extended the picture, linking tirzepatide to improvements in obstructive sleep apnea-related cardiometabolic risk markers. For a disorder in which excess adipose tissue drives airway collapse through anatomical loading, reduced lung volumes, and inflammatory and ventilatory effects, a drug that targets the underlying biology is not simply an adjunct. It is, for some patients, a disease-modifying therapy.

Yet the editorial’s central argument is not a celebration of pharmacology. It is a careful examination of professional boundaries. Sleep medicine specialists, the authors acknowledge, may feel conflicted about prescribing obesity-directed pharmacotherapy to improve sleep apnea. The sources of that conflict are concrete: uncertainty about scope of practice, weight stigma, operational burden, access and cost concerns, and limited training in weight management. For many sleep clinicians, the new era requires a shift from counseling patients about weight and referring medication management elsewhere, toward deciding which parts of weight management now belong within sleep medicine itself. Prescribing medication, the authors note, is generally within the legal reach of physicians, which makes this boundary more difficult to draw than those involving oral appliance fabrication or upper-airway surgery, where specialized technical skills clearly separate the fields.

To frame the problem, the editorial offers a geometric metaphor that is likely to circulate widely in sleep medicine education. Picture two overlapping circles. One circle is sleep medicine: diagnosis of sleep apnea, physiologic phenotyping, symptom assessment, positive airway pressure therapy, oral appliance therapy, surgical referral, adherence support, and objective reassessment of sleep-disordered breathing. The second circle is obesity medicine and metabolic care: obesity diagnosis and staging, pharmacotherapy, nutrition, physical activity, behavioral support, medication safety, cardiometabolic risk management, bariatric surgery referral, and weight maintenance. The overlap between the two circles is what the authors call obesity-informed sleep apnea care, and it is in this intersection that the future of the specialty is being negotiated.

Crucially, the authors insist that this overlap does not require every sleep physician to become an obesity medicine specialist. What it does require is enough competence, structure, and humility to guide patients through a therapy that now directly touches the sleep disorder being treated. In the overlap zone, sleep clinicians identify patients with sleep apnea and obesity who may benefit from weight-based therapy, counsel without stigma, explain that weight loss may improve but not necessarily eliminate sleep apnea, integrate pharmacologic weight-loss therapy with positive airway pressure and other established treatments, monitor sleep-specific outcomes, and determine when repeat sleep testing is needed. The editorial is equally clear about what should not happen. Abdication, treating obesity pharmacotherapy as someone else’s concern even when it alters apnea severity, symptoms, hypoxic burden, and follow-up testing, serves no one. Neither does overreach, the assumption that every sleep physician must deliver comprehensive obesity care.

The distinction between the overlap zone and comprehensive obesity medicine is drawn with technical precision. Full obesity medicine encompasses complete obesity staging, long-term pharmacologic management across multiple indications, complex adverse-effect monitoring, nutritional assessment, medication interactions, eating disorder concerns, pregnancy considerations, bariatric surgery selection, weight-regain management, stigma management, and longitudinal cardiometabolic care. Some sleep physicians may pursue this deeper expertise, including formal certification through the American Board of Obesity Medicine, a pathway the authors encourage. But they argue that such certification should not define the minimum identity of a sleep specialist. The analogy they invoke is restless legs syndrome, a condition in which sleep clinicians routinely evaluate iron status and prescribe iron therapy while recognizing that complex anemia, malabsorption, pregnancy, or kidney disease may require broader medical evaluation. The boundary, they write, is neither abandonment nor annexation. It is competent ownership of the sleep-relevant problem, with collaboration when the underlying condition exceeds sleep-specific expertise.

From this conceptual framework, the editorial derives a practical implementation model with three layers. The first is universal sleep medicine competency: every sleep physician should understand obesity as a chronic, biologically mediated disease rather than a failure of willpower, know the sleep apnea-relevant evidence for incretin-based therapies, counsel respectfully, recognize when medication may enter the treatment conversation, and know when to refer. The second is structured co-management, in which sleep centers build explicit pathways with primary care, endocrinology, obesity medicine, clinical pharmacy, nutrition, behavioral health, and bariatric surgery. The third is advanced sleep-obesity practice, in which some programs pursue deeper expertise through obesity medicine certification or establish embedded metabolic sleep clinics. This tiered architecture acknowledges the variable readiness of practices, from referral-only models to fully integrated metabolic sleep programs, and it converts a broad clinical question into an actionable agenda.

The institutional machinery behind this shift is already in motion. The American Academy of Sleep Medicine convened an Obesity Management Task Force in 2025 to discover emerging best practices, develop practical member resources, and propose a longer-term strategy. The task force curated physician- and patient-facing resources, modeled obesity management approaches across different practice settings, and surveyed Academy members about readiness, barriers, and implementation needs. In March 2026, the AASM Obesity Management Strategy Summit brought together task force members, Academy leadership and staff, and invited stakeholders from obesity medicine, bariatric surgery, endocrinology, nutrition, and patient advocacy. Through foundational presentations, small-group discussions, multivoting, and effort-impact prioritization, participants identified gaps and staged potential responses. The resulting summit summary, the editorial argues, is more than a meeting report; it is a field map showing where consensus is emerging, where evidence remains incomplete, and where implementation will demand shared work across clinical guidance, education, referral pathways, insurance coverage, stigma reduction, patient engagement, and workforce development.

The educational implications reach into the structure of training itself. The authors call for fellowship curricula that address the bidirectionality of obesity and sleep apnea, weight management pharmacotherapy, respectful communication, medication safety, outcome monitoring, and collaborative care models. Continuing education should help practicing clinicians understand indications, risks, monitoring requirements, and referral thresholds. Future clinical guidelines, they argue, must specify how pharmacologic weight management integrates with positive airway pressure, oral appliances, surgery, positional therapy, and follow-up testing. Accredited sleep centers, they suggest, may eventually need to demonstrate not that they prescribe obesity medications, but that they maintain a coherent pathway for patients who have both sleep apnea and obesity. The textbook of five years from now, the editorial predicts, should contain a serious section on metabolic sleep medicine covering obesity physiology, incretin-based therapies, bariatric surgery outcomes, indications and contraindications for medical or surgical obesity treatment, repeat testing after weight loss, residual sleep apnea, equity of access, stigma, and adherence, without becoming a bariatric medicine textbook in its own right.

The deeper significance of this editorial lies in how it reframes a therapeutic disruption as an exercise in professional self-definition. Grunstein and colleagues originally asked whether incretin-based pharmacotherapy would be a revolution or a pipe dream. The answer, the authors conclude, is neither fantasy nor simple replacement of existing therapies. It is a disruption that demands clinical architecture: clear decisions about which parts of obesity management are necessary for excellent sleep apnea care, which require structured collaboration, and which belong primarily to comprehensive obesity medicine. If sleep medicine answers that question with discipline, humility, and vision, the field can expand its therapeutic reach without losing its center of gravity, and millions of patients whose breathing pauses at night are driven by biology that a prescription can now address may finally receive care designed for the whole of their disease.

Subject of Research: Integration of obesity pharmacotherapy into obstructive sleep apnea care

Article Title: Obesity-informed OSA care: defining the expanding boundary of sleep medicine

Article References: Morgenthaler, T. I., Sepulveda, R., Bandyopadhyay, A., Hawa, R., Khan, S. S., Nowalk, N. C., Stager, L., Tadros, M., Tu, X., Vieira, N. M., & Wojeck, B. (2026). Obesity-informed OSA care: defining the expanding boundary of sleep medicine. Journal of Clinical Sleep Medicine, 22(1), Article 144. https://doi.org/10.1007/s44470-026-00157-w

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00157-w

Keywords: obstructive sleep apnea, obesity medicine, tirzepatide, incretin therapies, sleep medicine, SURMOUNT-OSA, weight management, AASM, positive airway pressure, metabolic sleep medicine, clinical guidelines, medical education

Obstructive sleep apnoea is far more than loud snoring. The disorder involves repeated collapse of the upper airway during sleep, cutting off airflow dozens or even hundreds of times per night. Each episode starves the body of oxygen, fragments sleep, and triggers surges of stress hormones. The consequences accumulate silently: untreated apnoea is linked to hypertension, myocardial infarction, stroke, and increased all-cause mortality. More than 425 million adults aged 30 to 69 are estimated to have the moderate-to-severe form of the disease, making it one of the largest underrecognised burdens in modern medicine.

Obesity sits at the centre of this epidemic. Excess fat deposited around the upper airway increases the throat’s tendency to collapse, while visceral abdominal fat impairs ventilatory control, reduces lung volumes, and diminishes the traction that normally helps hold the airway open. More than 60 percent of moderate-to-severe sleep apnoea cases are attributable to obesity, and disease severity tracks closely with body mass index. Weight reduction has long been a cornerstone of non-drug management, but until now clinicians have lacked answers to two crucial questions: how fast must the weight come off, and how much is enough to change the disease trajectory?

The new study drew on the SURMOUNT-OSA programme, two 52-week, randomised, double-blind, placebo-controlled phase 3 trials that tested tirzepatide, a dual GIP and GLP-1 receptor agonist already approved by the United States Food and Drug Administration for treating moderate-to-severe sleep apnoea in adults with obesity. Trial 1 enrolled participants not using positive airway pressure therapy, while trial 2 enrolled those already on it. In total, 469 participants were included in the analysis, with baseline apnoea-hypopnoea index values around 50 events per hour, indicating severe disease, and average body mass index near 39 kilograms per square metre.

The researchers retrospectively divided participants into four groups based on weight change at week 20: less than 5 percent, 5 to 10 percent, 10 to 15 percent, and 15 percent or more. The results revealed a clear dose-response relationship. In both trials, participants who achieved 15 percent or greater early weight reduction showed significantly greater reductions in the apnoea-hypopnoea index at both week 20 and week 52 compared with those losing less than 5 percent or 5 to 10 percent. The pattern held for percentage change in AHI as well, and across both trials, greater early weight loss correlated with greater AHI reduction at one year.

The remission data were the most eye-catching. By week 52, nearly half of trial 1 participants in the 10-to-15 percent early weight loss group had achieved OSA remission, defined as an AHI below 5 events per hour, or an AHI of 5 to 14 with minimal daytime sleepiness, and the remission rate reached 50.7 percent among those losing 15 percent or more. In trial 2, the picture was even more dramatic: 75.3 percent of participants with 15 percent or greater early weight loss achieved remission, with an odds ratio of 11.4 compared with the lowest weight loss group. By contrast, remission rates in the under-5 percent group languished between roughly 12 and 14 percent in both trials.

Beyond the breathing metrics, the analysis captured improvements in sleep apnoea-specific hypoxic burden, a measure of how much oxygen deprivation the body endures each hour. Participants in the highest weight loss category saw reductions of roughly 69 to 89 percent in this burden by week 52, far exceeding the improvements seen in lighter losers. Patient-reported outcomes told a parallel story, with significantly greater reductions in sleep disturbance and sleep-related impairment scores among the higher weight loss groups, alongside better physical component and general health scores on the SF-36 questionnaire.

The cardiometabolic ripple effects were equally notable. Participants achieving at least 10 percent early weight reduction showed improvements in systolic and diastolic blood pressure, high-density lipoprotein cholesterol, triglycerides, and inflammatory markers at follow-up, all of which are central to the cardiovascular risk that makes sleep apnoea so dangerous. Subgroup analyses suggested the benefits were consistent across age groups and disease severity, although participants with moderate apnoea showed meaningful improvement even with 5 to 10 percent early weight loss, while severe cases generally required the 10 percent or greater threshold.

Safety findings were reassuring across all weight loss categories, with no difference in serious adverse events between groups and no deaths related to adverse events. Gastrointestinal symptoms such as diarrhoea, nausea, and constipation were the most common side effects, consistent with the known profile of incretin-based therapies, and were generally mild to moderate in severity.

The authors caution that the analysis was not pre-specified, that grouping participants by observed weight loss introduces potential selection bias, and that the 52-week follow-up leaves longer-term durability uncertain. The trial population, drawn from 60 sites across nine countries, may also not fully represent the broader clinical population. Still, the implications are hard to ignore. If the magnitude of weight loss at week 20 proves to be a reliable prognostic marker, it could serve as a clinical decision point: patients responding robustly could be encouraged to continue intensive weight management, while those losing less than 5 percent might prompt timely escalation of therapy, whether through intensified lifestyle intervention, optimised pharmacotherapy, or initiation of positive airway pressure. In a field where treatment has often been reactive, the study suggests that the earliest months of weight loss may hold the key to rewriting the long-term course of one of the world’s most common chronic diseases.

Subject of Research: The relationship between early body weight reduction and long-term treatment outcomes in obstructive sleep apnoea with obesity

Article Title: Association between early body weight reduction and treatment outcomes in participants with obstructive sleep apnoea and obesity: a post hoc analysis of SURMOUNT-OSA trials

Article References: Lin, Y. N., Sun, X. W., Dai, S. J., Zhuang, H. X., Liu, J. J., & Li, Q. Y. (2026). Association between early body weight reduction and treatment outcomes in participants with obstructive sleep apnoea and obesity: a post hoc analysis of SURMOUNT-OSA trials. eClinicalMedicine, 100, Article 104203. https://doi.org/10.1016/j.eclinm.2026.104203

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104203

Keywords: obstructive sleep apnoea, obesity, weight loss, tirzepatide, SURMOUNT-OSA, apnoea-hypopnoea index, GLP-1 receptor agonist, hypoxic burden, cardiometabolic risk, sleep medicine, eClinicalMedicine, OSA remission

The original SURMOUNT-OSA program comprised two Phase 3, randomized, double-blind, placebo-controlled trials spanning 52 weeks. Study 1 enrolled 234 adults with moderate-to-severe sleep apnea, defined as an apnea-hypopnea index of at least 15 events per hour, and obesity, defined as a body mass index of at least 30 kilograms per square meter, who were not using PAP therapy. Study 2 enrolled 235 similar participants who were on PAP therapy, and asked them to withhold the device for roughly seven days before laboratory polysomnography so that their underlying disease severity could be measured. Participants received either the maximum tolerated dose of tirzepatide, 10 or 15 milligrams, or placebo. The primary results, published previously, showed clinically meaningful reductions in the apnea-hypopnea index, in sleep apnea-specific hypoxic burden, in body weight, and in systolic blood pressure, along with improvements in high-sensitivity C-reactive protein and patient-reported outcomes.

The new analyses asked a deceptively simple question: did the drug work equally well in everyone, or did its effectiveness depend on who the patient was at the start of the trial? The researchers stratified participants by baseline age, sex, apnea-hypopnea index severity, body mass index, and neck circumference, then estimated changes from baseline to week 52 using mixed models for repeated measures, adjusting for baseline values, geographic region, sex, and treatment. Because these exploratory analyses were descriptive rather than powered for formal statistical testing of heterogeneity, the authors caution that apparent differences between subgroups may reflect chance, residual confounding, differing baseline distributions, or regression to the mean. Still, the consistency of the direction of benefit across nearly every slice of the population is striking.

The headline finding is that tirzepatide outperformed placebo across all baseline subgroups. Participants on the drug experienced apnea-hypopnea index reductions ranging from roughly 20 to more than 50 events per hour depending on subgroup, compared with far smaller changes on placebo. When stratified by age, reductions ranged from 27.7 to 34.1 events per hour; by sex, from 19.8 to 32.6 events per hour; by baseline apnea-hypopnea index, from 12.1 to 52.2 events per hour; by body mass index, from 25.2 to 34.4 events per hour; and by neck circumference, from 23.9 to 30.8 events per hour. Sleep apnea-specific hypoxic burden, an emerging measure of the oxygen deprivation burden imposed by the disease, and systolic blood pressure also improved consistently, with blood pressure falling by roughly 6.7 to 10.2 millimeters of mercury across subgroups and studies—a magnitude that rivals or exceeds the modest reductions typically achieved with PAP therapy itself.

Some of the numerical patterns tracked physiology in intuitive ways. Men, who had higher baseline apnea-hypopnea indices than women in both trials, posted larger absolute reductions, from 30.6 events per hour in men versus 19.8 in women in Study 1, and 32.6 versus 24.8 in Study 2. Participants with the most severe disease at baseline, an apnea-hypopnea index of at least 70 events per hour, saw the largest absolute drops, at 43.3 events per hour in Study 1 and 52.2 events per hour in Study 2, although their relative improvement was smaller than in patients with milder disease. Younger participants on PAP therapy in Study 2 showed numerically greater reductions in the apnea-hypopnea index, hypoxic burden, and body weight than those aged 50 and older, hinting that obesity may play a stronger causal role in sleep apnea among younger patients, while age-related factors such as reduced lung function and weakened upper airway protective reflexes may dilute the benefit of weight loss in older adults.

Perhaps the most clinically resonant results concern categorical shifts in disease severity. Among tirzepatide-treated participants, 67.7 percent in Study 1 and 79.0 percent in Study 2 moved to a less severe apnea category by week 52, whereas most placebo participants, 64 to 70 percent, saw no clinically relevant change. Improvement crossed every baseline characteristic examined: by age, 62.4 to 77.8 percent of tirzepatide-treated participants improved depending on subgroup and study; by sex, 60.5 to 86.1 percent; and by body mass index, the proportion improving ranged from 57.0 to 80.5 percent. Even in the very severe subgroup with a baseline apnea-hypopnea index of at least 70 events per hour, where average starting values hovered around 86 to 91 events per hour, over half of tirzepatide-treated participants in both studies achieved reductions of at least 50 percent, and 31.8 to 64.6 percent improved in severity class.

The neck circumference findings add a physiologically interesting wrinkle. Neck circumference has been proposed as a better proxy than body mass index for the fat deposition around the upper airway that narrows breathing passages during sleep. Participants with larger necks, who tended to be younger, male, and heavier, showed numerically greater absolute reductions in apnea-hypopnea index and body weight than those with smaller necks, a pattern consistent across both studies. Meanwhile, weight reductions increased with higher baseline body mass index, particularly in Study 2, and apnea-hypopnea index improvements were broadly similar across body mass index categories, suggesting that patients with even the highest degrees of obesity stand to benefit. The authors note that these results contradict the assumption that heavier patients would need to lose more weight to achieve comparable airway improvement.

Underlying the results is a central scientific question: how much of tirzepatide’s effect on sleep apnea flows through weight loss, and how much is independent? A separate analysis of the SURMOUNT-OSA data found a linear association between the magnitude of weight reduction and improvements in the apnea-hypopnea index and hypoxic burden, pointing to weight loss as the dominant driver. But the authors caution that weight-independent effects cannot be excluded. Tirzepatide may influence several of the pathogenic pathways that produce sleep apnea, including insulin resistance and systemic inflammation, both of which have been identified as antecedent risk factors for the disorder and may affect airway muscle function and ventilatory control. Sex differences in these pathways, and evidence from other studies that women tend to lose more weight on incretin therapies than men, may help explain why weight changes by sex were inconsistent between the two trials even as apnea measures improved in both.

The authors are careful about the limitations. The 52-week duration of the trials leaves the long-term effects unknown, particularly since longer studies of tirzepatide have shown additional weight loss over time. Subgroup analyses were not powered for statistical significance, the models did not mutually adjust for all baseline characteristics, and factors such as socioeconomic status, prior apnea surgery, PAP adherence, and apnea endotypes were not captured. Discontinuation rates were also higher in the placebo arm, which may have inflated the apparent treatment difference. Still, the consistency of benefit across two independent trials, nearly five hundred participants, and every baseline characteristic examined represents an unusually robust signal for an exploratory analysis.

For clinicians and patients, the practical takeaway is considerable. Severity improvements on tirzepatide may open the door to alternative therapies such as oral appliances or positional therapy for patients shifted into milder disease categories, and the substantial blood pressure reductions may carry independent cardiovascular significance given the known links between sleep apnea, resistant hypertension, and cardiometabolic disease. Whether tirzepatide and PAP therapy together produce additive benefits, and whether the improvements endure over years, remain open questions that the authors say warrant further study. What is already clear is that the era of treating sleep apnea with machines alone is ending, and that a single medication can meaningfully reshape the disease across virtually the full spectrum of patients who have it.

Subject of Research: Effects of tirzepatide on obstructive sleep apnea severity and cardiometabolic measures across baseline patient subgroups in the SURMOUNT-OSA Phase 3 trials

Article Title: Association of tirzepatide with changes in OSA-related measures based on baseline characteristics – post hoc analyses of SURMOUNT-OSA

Article References: Falcon, B., Xie, C. C., Redline, S., Grunstein, R., Turnbull, C. D., Rapoport, D. M., Wang, H., Chakladar, S., Dimitriadis, G. K., Lau, E., Bednarik, J., Liao, B., & Malhotra, A. (2026). Association of tirzepatide with changes in OSA-related measures based on baseline characteristics – post hoc analyses of SURMOUNT-OSA. Journal of Clinical Sleep Medicine, 22(1), Article 155. https://doi.org/10.1007/s44470-026-00162-z

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00162-z

Keywords: tirzepatide, obstructive sleep apnea, SURMOUNT-OSA, obesity, GLP-1 receptor agonist, apnea-hypopnea index, hypoxic burden, blood pressure, weight loss, sleep medicine, Phase 3 trials, post hoc analysis